We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Companies Collaborate to Detect Gene Rearrangements

By LabMedica International staff writers
Posted on 04 Dec 2012
A collaboration between two companies aims to develop an automated scanning solution to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in patients with advanced non-small-cell lung cancer (NSCLC).

BioView (Rehovot, Israel) and Abbott (Abbott Park, IL, USA) will collaborate on automated fluorescent in situ hybridization (FISH) scanning for the Vysis ALK probe kit. More...
According to an agreement between the two companies, BioView will perform the studies to obtain regulatory approval for its Duet Automated Scanner to include an indication for automated imaging and analysis of Abbott's Vysis ALK Break Apart FISH Probe Kit.

Abbott plans to utilize the BioView product in its own clinical trials for future regulatory approval for end-to-end automation of the preparation, scanning, and scoring of formalin-fixed paraffin-embedded (FFPE) non-small-cell lung cancer-tissue specimens, probed with the ALK Kit. After receiving regulatory approvals, the parties plan to co-promote the BioView product worldwide, in compliance with applicable regulatory rules.

The Duet System is intended for in vitro diagnostic use as tool to aid the pathologist in the detection, classification, and counting of cells of interest based on color, intensity, size, pattern, and shape. The Duet has US Food and Drug Administration (FDA; Silver Springs, MD, USA) clearances for the automated imaging and analysis of hematopoietic cells, amniotic cells, cells in urine, and FFPE breast tissue specimens.

Related Links:

BioView
Abbott
US Food and Drug Administration




Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.